Immunity to Theileria parva infection in cattle is often parasite stock specific. The antigenic diversity which is expressed at the schizont stage of the parasite together with a wild reservoir of the organism in buffalo has complicated the development of effective disease control by immunization. We have previously shown that about 70% of cattle inoculated with recombinant forms of p67, a sporozoite stage-specific surface antigen from the cattle-derived Muguga stock of the parasite, are immune to a homologous challenge. Thus, immune responses to p67 can play a role in immunity. The genes encoding this protein in five other parasite stocks have been sequenced. Here, we report that the p67 molecule encoded by four cattle-derived parasite stocks (Boleni, Uganda, Mariakani, and Marikebuni) that fall into different cross-immunity groups is identical in sequence to Muguga p67. The protein encoded by a buffalo-derived parasite exhibits 95% sequence identity with Muguga p67, the major difference being the presence of a 43-residue peptide insert. As predicted by these data, cattle inoculated with recombinant p67 can resist a heterologous cattle-derived parasite challenge. Seven of 12 cattle receiving a homologous Muguga challenge and 6 of 11 cattle receiving a heterologous Marikebuni challenge were immune to East Coast fever. These results extend earlier data suggesting that p67 is a conserved molecule and confirm its potential as a broad-spectrum vaccine antigen for the control of T. parva infection.
Cattle are a major economic resource in Africa, and bovine theileriosis caused by the tick-transmitted protozoan parasite Theileria parva is a constraint to the development of this livestock industry in large parts of sub-Saharan Africa. The disease is a lymphoproliferative disorder which usually causes death within 3 to 4 weeks after infection (reviewed in reference 8).
On the basis of certain behavioral characteristics, T. parva has, in the past, been divided into three ''subspecies'' (34; reviewed by Norval et al. [28] ). Under this nomenclature, T. parva parva is the cause of East Coast fever (ECF), and T. parva bovis is the cause of January disease. These two subspecies are maintained in cattle, whereas buffalo are asymptomatic carriers of T. parva lawrencei, which causes Corridor disease in cattle. January disease, so called because of its seasonal transmission, occurs in Zimbabwe, Zambia, Malawi, and southern Tanzania, whereas ECF and Corridor disease are widespread in eastern, central, and southern Africa. With the advent of molecular characterization techniques, it has become increasingly clear that there is little biological justification for division of T. parva into subspecies, and it has been recommended that parasite stocks be described as either cattle-or buffalo-derived parasites (1) .
Animals that recover naturally from infection acquire immunity to a homologous challenge. Immunity can be induced by infection with cryopreserved sporozoites, the infective life cycle stage, and treatment with tetracycline (30) or the antitheilerial drugs which are used for chemotherapy (14) . Cattle immunized by infection and treatment undergo a mild to moderate disease reaction with transient pyrexia and schizont parasitosis (reviewed in reference 19) . Immunity in recovered cattle is believed to be dependent primarily on cell-mediated responses (6) , and control of the infection is believed to be mediated by CD8 ϩ major histocompatibility complex class Irestricted cytotoxic T lymphocytes specific for schizont-infected host cells (15, 17) . One of the problems associated with the wide-scale application of the infection and treatment method of immunization is that the immunity appears to be strain specific, and heterologous cattle-derived parasite challenges often result in disease (7, 31) . For example, 30 to 40% of cattle immunized with the Muguga stock are susceptible to a Marikebuni challenge, whereas all cattle immunized with the Marikebuni stock are immune to a Muguga challenge (7, 18) . Most in vitro studies have concentrated on these two parasite stocks and they are thus the best characterized, although the cross-immunity profiles for a number of different parasite stocks have been established (7, 24) . The Muguga stock is a relatively homogeneous parasite stock, while the Marikebuni stock contains several genotypes, which probably accounts for its broad cross-protective capacity (4, 24, 33) . Although the bovine major histocompatibility complex is a complicating factor in interpreting the data, it is likely that antigen heterogeneity (17, 29, 33) contributes to the breakdown in the immunity to reinfection. In sharp contrast to the specificity of the cell-mediated cytolytic immune response to infection, antibodies to sporozoites of the Muguga parasite stock are able to cross-neutralize sporozoites from different stocks, e.g., Uganda, Marikebuni, and Mavueni, suggesting that sporozoite antigens could be the basis of a broad-spectrum vaccine against T. parva (5, 22) . In the first step towards testing this hypothesis, we cloned and expressed DNA coding for p67 (23, 26) , a sporozoite stagespecific membrane protein, from the Muguga stock of T. parva (3) , an ECF-causing, cattle-derived parasite which has been maintained in the laboratory for over 30 years. We reported that cattle inoculated with recombinant forms of p67 can exhibit immunity to a homologous challenge that is lethal to control animals (21, 27) . The success of the antisporozoite approach can in part be attributed to the observation that the severity of ECF in cattle is sporozoite dose dependent (9) .
A detailed knowledge of the extent of p67 amino acid sequence polymorphism, particularly among field isolates of T. parva, is important for vaccine development, since variation in the sequence of determinants, which either generate or are the targets of protective immune responses, could lead to vaccine failure. We have determined the DNA sequences of the genes encoding p67 of six reference T. parva stocks, including T. p. bovis and T. p. lawrencei. Our finding is that the predicted amino acid sequence of p67 of cattle-derived T. parva is invariant, while the buffalo-derived parasite p67 protein contains a small degree of polymorphic sequences. In addition, we have challenged cattle inoculated with NS1-p67, an Escherichia coliderived recombinant fusion protein of Muguga p67, with heterologous cattle-derived sporozoites from the Marikebuni stock and demonstrate protection levels similar to those obtained with a homologous challenge. These results confirm that p67 has the potential of being a widely applicable vaccine antigen.
MATERIALS AND METHODS
Parasite stocks and nucleic acids. Genomic DNA preparations were made from purified piroplasms or schizont-infected lymphoblastoid cell lines (4) . DNAs from six reference parasite stocks, Boleni (11), Mariakani (7), Marikebuni (7), Muguga (3), Uganda (16) , and buffalo 7014 (20) , were used. The International Livestock Research Institute parasite reference numbers for these stocks are 3039, 3319, 3014, 3087, 3066, and 3081, respectively. The Boleni stock was formerly described as T. p. bovis, and buffalo 7014 was described as T. p. lawrencei. The parasites were isolated from Boleni Farm, Goromonzi, Zimbabwe, and Ol Pejeta Ranch, Laikipia District of Kenya, respectively. The remaining stocks were all formerly described as T. p. parva and originate from northwestern Uganda and the Kiambu (Muguga) or Kilifi district of Kenya. T. parva Schoonspruit DNA was kindly provided by B. Allsopp and originates from South Africa before ECF was eradicated (25) .
oligo(dT)-primed first-strand cDNA was made from RNA prepared from salivary glands dissected from T. parva-infected ticks as described previously (26) . Briefly, adult ticks that had been allowed to feed on a naturally infected buffalo as nymphs were allowed to feed on rabbits. Four days later, the salivary glands were removed from the ticks and flash frozen in liquid nitrogen. The tissue was ground to a fine powder, and total RNA was prepared by a hot phenol-sodium dodecyl sulfate procedure and then enriched for poly(A) ϩ sequences by oligo(dT)-cellulose chromatography. First-strand cDNA was primed with oligo(dT), and low-molecular-weight components were removed by centrifugation through an Amicon Centricon C 30 column. An aliquot of this material was subjected to PCR.
PCR amplification and sequence analysis of the gene encoding p67. Synthetic oligonucleotides IL 246 (CGACACTGAACGATGCAAATA) and IL 247 (GAGTTATTGTTAGTGGACGAT), which overlap the 5Ј and 3Ј ends of the p67 gene (26) , respectively, were used in a standard PCR (30 cycles of 1 min at 95ЊC, 1 min at 55ЊC, and 1 min at 74ЊC; 1.5 mM MgCl 2 ) to amplify a 2.2-kbp DNA fragment from parasite genomic DNA. Initially, PCR products were cloned into T-tailed plasmid vectors (13) and sequenced by using a Sequenase kit (Promega) and a series of internal p67-specific synthetic oligonucleotides. PCR products were also subjected to direct sequence analysis using the fmol cycle sequencing kit (Promega). In some cases in which terminal sequences were difficult to complete, it was assumed that the sequences of primers IL 246 and IL 247 were present in the amplified product. Two primers, IL 613 (ACAAACAC AATCCCAAGTTC) and IL 792 (CCTTTACTACGTTGGCG), were used to amplify a 900-bp internal gene fragment from first-strand infected-tick salivary gland cDNA.
Immunization and challenge of cattle. Twenty-three Boran (Bos indicus) cattle aged 4 to 6 months and negative for T. parva antibodies were inoculated as previously described (21) . Briefly, the cattle received a total of five inoculations, each one consisting of 600 g of a semipurified preparation of NS1-p67 formulated in 3% saponin. All cattle were maintained under strict acaricidal control. Antigen boosters were given at 30-day intervals, and 14 days after the final inoculation, 12 cattle were challenged with one 68% lethal dose of T. parva (Muguga) sporozoite stabilate 3087, while the remaining 11 cattle received a challenge of 1 ml of a 1:8 dilution of T. parva (Marikebuni) sporozoite stabilate 3014. Ten naive cattle served as sporozoite challenge controls for each of the parasite stabilates. Clinical reactions and parasitological parameters were monitored as previously described (2), and animals undergoing a severe disease reaction were euthanized.
Specific p67 antibody responses in immunized cattle. Titers of antibody to p67 were measured by sandwich enzyme-linked immunosorbent assays (ELISAs) using monoclonal antibody ARIII 21.4 to trap recombinant p67 produced by a baculovirus expression system (27) . Serum samples were taken prior to inoculations and then at weekly intervals during the experimental period. The binding of bovine antibodies was quantitated by using horseradish peroxidase-conjugated goat anti-bovine immunoglobulin. The specificity of the bovine sera was also tested by immunoblot analysis of DEAE-purified sporozoites (21) . The same material was used for measuring sporozoite neutralization titers. Briefly, peripheral blood mononuclear cells were incubated with a suspension of sporozoites in the presence of test antiserum. The reciprocal of the dilution of serum that gave Ͼ90% inhibition of schizont parasitosis 14 days after culture was defined as the sporozoite neutralizing-antibody titer (21) . Preinoculation serum from each animal was used as the negative control for ELISAs and sporozoite neutralization assays.
Nucleotide sequence accession number. The nucleotide sequence of the buffalo 7014 p67 gene has been submitted to GenBank under accession no. U40703.
RESULTS
Sequence analysis of the gene encoding p67. Standard PCR conditions were used to amplify the gene encoding p67 from genomic DNA preparations of several T. parva stocks, and all possible precautions were taken to prevent contamination of reagents. A single 2.2-kbp DNA fragment spanning the two p67 exons and the 29-bp cis-spliced intron (26) was amplified from the DNA of all stocks examined. Initially, we determined the sequence of PCR products that had been cloned into Ttailed plasmid vectors (13) . However, the sequences of cloned PCR products from the same amplification reaction contained different point mutations, and it soon became apparent that Taq polymerase errors (32) were compromising the sequence data. For example, comparison of the T. parva Muguga PCR product sequence with the previously published genomic DNA sequence revealed an average of five nucleotide substitutions per clone (data not shown). Rather than use other heat-stable DNA polymerases which are reported to have a greater proofreading capacity (12), we opted to subject the PCR products to direct analysis by cycle sequencing. Unless an error occurs early during the amplification reaction, the sequencing ladder is a faithful representation of the template sequence.
The genomic DNA sequences of the p67 PCR products amplified from the T. parva Boleni, Muguga, Marikebuni, Mariakani, and Uganda parasite stocks were determined and found to be identical to each other and to the previously published sequence (GenBank accession no. M67476) of the gene encoding p67 from the Muguga stock (26) . Thus, all these cattle-derived parasite stocks are predicted to encode identical p67 molecules. The genomic DNA sequence of the PCR product of buffalo 7014, however, was different. When compared with the Muguga p67 sequence, it was found to contain several nucleotide substitutions and a 129-nucleotide insertion (Fig.  1) . A 29-bp sequence identified as an intron in the Muguga p67 gene was present in all the sequences; the 129-bp insert in buffalo 7014 is located 37 bp upstream of the intron. We have not directly confirmed that the 29-bp sequence functions as an intron in all the genes, but this is a reasonable assumption, given the sequence conservation and the fact that the sequence disrupts the p67 open reading frame. The 129-bp insert did not have the characteristics of T. parva introns (26), and we predicted that the sequence would encode a 43-amino-acid insert in p67. Because of the lack of sporozoites from the buffalo 7014 parasite stock, we analyzed sporozoite mRNA from an unrelated but buffalo-derived parasite stock. An internal 900 bp of p67 DNA was amplified from first-strand cDNA of infectedtick salivary glands, and 496 bp of DNA encoding the region of interest was sequenced. This DNA was found to be identical, except for the absence of the 29-bp intron, to the 7014 genomic p67 DNA sequence. Thus, we have confirmed that the 129-bp insertion is present in cDNA. Figure 1 depicts the DNA sequence of the gene encoding p67 of buffalo 7014 and the predicted translation product. Of 63 nucleotide sequence differences between the Muguga and buffalo 7014 gene sequences, 18 are located in the first base position of codons, 15 are in the second position, and 28 are in the third position; two substitutions occupy the first and third positions of one codon. Because of degeneracy of the genetic code, only 3 of the 28 third-position changes resulted in altered amino acid identity, whereas all of the second-position changes and 17 of the 18 first-position changes resulted in altered amino acid identity. The doubly substituted codon also changes amino acid identity. Buffalo 7014 p67 is predicted to contain a total of 752 amino acid residues, while Muguga p67 contains 709 residues (26) . The calculated molecular weights of the two proteins are 79,544.80 and 75,437.62, respectively, and the features associated with Muguga p67, namely, an N-terminal signal sequence and a hydrophobic C-terminal region (26) , are found in buffalo 7014 p67. Both proteins have seven consensus sites for N-linked glycosylation but at different locations. Disregarding the 43-amino-acid peptide insert, in comparison with Muguga p67, the buffalo 7014 protein contained only 36 amino acid substitutions, and the two p67 proteins exhibited an overall sequence identity of 95% or a similarity of 99.4%, when conservative amino acid substitutions were taken into consideration. Figure 2 shows a sequence alignment of Muguga p67 against buffalo 7014 p67 in the form of a diagon plot. The break in the alignment marks the position of the 43-residue peptide insert.
Immune responses in cattle inoculated with NS1-p67. Twenty-three cattle were each given five inoculations of NS1-p67, a recombinant form of p67 derived from the Muguga stock of T. parva, formulated with saponin as the adjuvant. The specificities of antibody responses detected were similar to those previously described (21) . Tables 1 and 2 summarize the sandwich ELISA antibody titers in serum samples taken prior to sporozoite challenge; the titers ranged from 1:12,500 to 1:62,500. One animal had a sporozoite neutralization titer of 1:300, but the majority of the cattle had neutralization titers of Ն1:500. All sera bound to native p67 in an immunoblot analysis of sporozoite lysates, and antibody titers determined by this test varied from 1:5,000 to 1:15,000 (data not shown).
Sporozoite stabilate challenges. To test whether p67 can induce cross-immunity to a heterologous sporozoite challenge, 11 of the 23 inoculated cattle were given a challenge with Marikebuni 3014 sporozoites and the remaining 12 cattle were given a homologous challenge with Muguga 3087 sporozoites. Cattle inoculated with control E. coli antigen formulated in saponin are susceptible to ECF (21) , and this antigen control was not included in this experiment. Ten naive cattle served as controls for each sporozoite stabilate.
Both sporozoite challenge doses used are known to cause severe ECF reactions in naive cattle. Although cattle exhibiting severe ECF may recover, such animals are considered susceptible to ECF (2). Thus, cattle that exhibit no ECF reaction or mild ECF reactions upon challenge exhibit immunity. Animals that undergo moderate ECF reactions are classified as immune or susceptible, depending on their clinical profile. In the experiments reported here, all cattle that experienced moderate disease reactions were classified as immune. The 20 control animals underwent severe ECF reactions, confirming the viability of the challenge, with a typical prepatent period of about 8 days. Seven of the 12 NS1-p67-inoculated cattle receiving a homologous Muguga challenge and 6 of the 11 cattle given a heterologous Marikebuni challenge were judged to be clinically immune to ECF (Tables 1 and 2 ). Thus, the two groups of cattle expressed similar levels of immunity to challenge. These results confirm the previously reported protective capacity of p67 and demonstrate that the immunity extends to heterologous parasite challenges.
DISCUSSION
Antigenic diversity between T. parva stocks is well documented (16, 29, 33) and is likely to be the cause of vaccine failure in cattle immunized by infection and treatment (8, 19, 23) . However, antibodies to p67, a sporozoite stage-specific surface antigen, of the Muguga parasite stock are able to neutralize sporozoites derived from heterologous parasite stocks, suggesting a conservation of at least some antigenic determinants on p67 (23) . We and others have previously reported that recombinant forms of p67 encoded by the Muguga stock are able to induce immunity against ECF in cattle; 10 of 15 cattle were immune to a homologous (Muguga) sporozoite challenge (21, 27) . Thus, this antigen is a prime antisporozoite vaccine candidate. Here, we have extended our studies of this vaccine antigen by determining the sequence of p67 encoded by several parasite stocks, and we have carried out a heterologous sporozoite challenge of cattle inoculated with NS1-p67, one of the recombinant forms of p67.
The gene encoding Muguga p67 is present in a single copy, and the protein-coding region consists of two exons split by an intron 29 bases long (26) . The DNA sequences of the genes encoding p67 of the Muguga, Marikebuni, Mariakani, Uganda, Boleni, and buffalo 7014 T. parva stocks were established by directly sequencing the PCR products of parasite genomic DNAs. The latter two parasite stocks have in the past been given the subspecies status of T. p. bovis and T. p. lawrencei (34) , respectively. Our data show that the T. parva parasite stocks which can be maintained by passage between cattle and the tick vector, that is, the Muguga, Marikebuni, Mariakani, Uganda, and Boleni stocks, contain identical p67 gene sequences. PCRs were repeated several times and with new re -FIG. 2 . Diagon similarity plot of p67 encoded by cattle-and buffalo-derived T. parva. The homology plot was derived by using the Hitachi Prosis program. The equivalence amino acid groups were not used, and the number of matching residues was set at 7 over a check size of 10. Cattle-type parasite p67 consists of 709 amino acid residues, while 7014-type p67 contains 752 residues. agents to rule out the possibility of nucleic acid contamination. Subsequent to this analysis, the same DNA preparations have been used to demonstrate sequence polymorphisms of an unrelated protein-coding gene (data not shown). This together with the polymorphism of buffalo 7014 p67 indicates that the result with cattle-derived parasite p67 sequences is not artifactual. We have also found that T. parva Schoonspruit, a stock isolated in 1937 in the Transvaal, South Africa (25), before ECF was eradicated, contains a p67 gene sequence identical to that of the Muguga parasite. Thus, the p67 gene sequences, and hence the predicted protein sequences of the sporozoite antigen, of cattle-derived T. parva parasites isolated in Kenya, Uganda, Zimbabwe, and South Africa are identical to each other. Although we have carried out a limited survey, it is tempting to speculate that all cattle-type parasites contain identical sporozoite p67 molecules. This situation is in contrast to that found for the equivalent sporozoite protein in Theileria annulata, which expresses polymorphic sequences (10) . The p67 sporozoite antigen encoded by buffalo 7014 was different from that found in cattle-derived parasites. The gene contained the 29-bp cis-spliced intron found in Muguga p67 DNA, but it had a 129-bp DNA insertion and 63 nucleotide substitutions. The presence of the DNA insert was confirmed with cDNA from an unrelated, buffalo-derived parasite which was identical in sequence to the buffalo 7014 gene. The sequence of the 3Ј intron-exon junction had altered from AG-GC in the Muguga gene to AG-GT in the buffalo 7014 gene. This nucleotide change did not affect splicing, since the intron sequence was not found in cDNA. The extra 129-bp DNA resulted in a 43-amino-acid peptide insert between amino acid residues 303 and 304 of Muguga p67. It is interesting that there is a duplication of the DNA sequence at the site of insertion (Fig. 1) , a feature often associated with transposable elements.
Regions of proteins which are functionally important are usually conserved in evolution, and it could be argued that the conservation of p67 sequences is related to its presumed role in sporozoite-host cell interactions. However, it is unusual to maintain complete sequence identity. The protein in buffalo 7014 sporozoites is not conserved, and preliminary data from a sequence analysis of other buffalo-derived parasite stocks indicate that p67 is more polymorphic than reported here. It is postulated that T. parva evolved in buffalo and that the parasite became adapted to cattle since their introduction into Africa in the fifth millennium B.C. (28) . There are clear phenotypic differences between cattle-derived and buffalo-derived parasites which may in some subtle way be reflected in our findings. For example, Corridor disease is a more acute disease than ECF, with extremely low parasitemias, and it is difficult to maintain the causative parasite by passage in cattle.
From the DNA sequence data, it is evident that the cattlederived parasites analyzed contain identical p67 proteins. Thus, protective immune responses generated by NS1-p67 should operate against any of these cattle-derived parasites, although they exhibit different cross-immunity profiles (7) . In order to test this hypothesis, we challenged cattle that had been inoculated with NS1-p67 with a heterologous (Marikebuni) sporozoite stabilate and compared the results with those for cattle given a homologous (Muguga) challenge. Protection c The reciprocal of the sandwich ELISA titer of antibody to insect cell p67 and sporozoite neutralization titer (NIT) of serum collected prior to sporozoite challenge are given.
was measured by evaluating parasitological and clinical parameters, with the duration and level of schizont parasitosis directly related to the severity of the disease. Similar levels of protection were observed in the two groups of cattle (Tables 1  and 2 ), clearly demonstrating that recombinant p67 is able to induce immunity to a heterologous parasite challenge.
Comparison of the clinical responses with ELISA and sporozoite neutralizing-antibody titers did not reveal any correlation with immunity to challenge. These results are qualitatively similar to our previously published data (21, 27) . Although the immunological parameters measured are useful indicators of antigen exposure, there is little predictive value in them. Preliminary data indicate that there is no difference in the anti-p67 antibody titers or sporozoite neutralization capacity between the immunoglobulin G1 and immunoglobulin G2 fractions of sera from immune and susceptible cattle (data not shown). We and others have reported previously that cattle inoculated with NS1-p67 had inconsistent T-cell proliferative responses (27) ; individual responses varied from zero to positive. Thus, T-cell responses were not measured in these experiments, and the role of p67-induced cell-mediated responses in protection is unclear. While the mechanism of the acquired immunity remains to be defined, it completely prevented disease in only a proportion of the inoculated cattle. Therefore, experiments to improve the level of protection are in progress.
For vaccines against T. parva infections, immunity against both the sporozoite and the schizont life cycle stages is desirable. Once protective schizont antigens that are the targets of CD8 ϩ T cells are identified, they can be used with p67 to develop vaccines directed against both life cycle stages of the parasite. A major implication of the reported results is that it is not likely that development of a p67-based antisporozoite vaccine will be hampered by antigenic diversity of cattle-derived parasites. The impact, if any, of buffalo-derived sporozoite challenges on a p67-based vaccine is being investigated.
